Korea Arlico PharmLtd Past Earnings Performance
Past criteria checks 0/6
Korea Arlico PharmLtd's earnings have been declining at an average annual rate of -25.5%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 12% per year.
Key information
-25.5%
Earnings growth rate
-33.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 12.0% |
| Return on equity | -10.7% |
| Net Margin | -5.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Korea Arlico PharmLtd (KOSDAQ:260660) Is Carrying A Fair Bit Of Debt
Nov 12
There's Reason For Concern Over Korea Arlico Pharm Co.,Ltd.'s (KOSDAQ:260660) Price
Aug 04Is Korea Arlico PharmLtd (KOSDAQ:260660) Using Too Much Debt?
Mar 24Should You Be Adding Korea Arlico PharmLtd (KOSDAQ:260660) To Your Watchlist Today?
Mar 02Korea Arlico PharmLtd's (KOSDAQ:260660) Shareholders Are Down 50% On Their Shares
Feb 12
What Is The Ownership Structure Like For Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)?
Jan 25Should You Use Korea Arlico PharmLtd's (KOSDAQ:260660) Statutory Earnings To Analyse It?
Jan 04Is Korea Arlico PharmLtd (KOSDAQ:260660) A Risky Investment?
Dec 16Are Strong Financial Prospects The Force That Is Driving The Momentum In Korea Arlico Pharm Co.,Ltd.'s KOSDAQ:260660) Stock?
Nov 25Revenue & Expenses Breakdown
How Korea Arlico PharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 178,827 | -8,865 | 101,115 | 5,526 |
| 31 Mar 24 | 183,958 | -1,369 | 100,938 | 4,258 |
| 31 Dec 23 | 187,155 | 3,061 | 101,581 | 4,180 |
| 30 Sep 23 | 186,794 | 7,281 | 99,006 | 3,907 |
| 30 Jun 23 | 184,088 | 9,943 | 96,815 | 4,251 |
| 31 Mar 23 | 172,363 | 7,701 | 91,940 | 5,147 |
| 31 Dec 22 | 167,737 | 8,034 | 89,281 | 6,532 |
| 30 Sep 22 | 162,933 | 8,617 | 85,334 | 7,739 |
| 30 Jun 22 | 155,676 | 5,807 | 80,655 | 9,628 |
| 31 Mar 22 | 151,732 | 5,663 | 78,858 | 9,316 |
| 31 Dec 21 | 140,157 | 4,930 | 73,618 | 8,194 |
| 30 Sep 21 | 130,924 | 3,774 | 70,487 | 6,883 |
| 30 Jun 21 | 127,368 | 6,579 | 68,665 | 4,371 |
| 31 Mar 21 | 124,436 | 7,387 | 66,161 | 3,676 |
| 31 Dec 20 | 124,809 | 8,372 | 65,058 | 3,142 |
| 30 Sep 20 | 126,019 | 10,800 | 63,342 | 2,606 |
| 30 Jun 20 | 122,859 | 11,050 | 61,745 | 1,905 |
| 31 Mar 20 | 120,229 | 10,950 | 60,057 | 1,862 |
| 31 Dec 19 | 115,793 | 10,031 | 58,413 | 1,817 |
| 30 Sep 19 | 111,609 | 9,573 | 56,736 | 1,811 |
| 30 Jun 19 | 105,864 | 8,183 | 54,198 | 2,090 |
| 31 Mar 19 | 100,502 | 6,597 | 51,859 | 2,396 |
| 31 Dec 18 | 95,338 | 1,218 | 49,030 | 2,037 |
| 30 Sep 18 | 87,297 | -1,805 | 44,263 | 2,203 |
| 30 Jun 18 | 82,803 | -2,092 | 40,626 | 2,006 |
| 31 Mar 18 | 77,032 | -1,757 | 36,226 | 1,972 |
| 31 Dec 17 | 71,358 | 3,339 | 32,136 | 1,945 |
| 30 Sep 17 | 66,342 | 4,062 | 29,902 | 1,857 |
| 30 Jun 17 | 60,887 | 4,156 | 26,838 | 1,747 |
| 31 Mar 17 | 53,883 | 3,292 | 24,216 | 1,281 |
| 31 Dec 16 | 48,127 | 2,243 | 21,545 | 1,336 |
| 31 Dec 15 | 32,986 | 624 | 13,552 | 1,771 |
| 31 Dec 14 | 29,639 | 501 | 11,151 | 1,228 |
| 31 Dec 13 | 28,730 | 767 | 9,182 | 1,207 |
Quality Earnings: A260660 is currently unprofitable.
Growing Profit Margin: A260660 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A260660 is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare A260660's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A260660 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.6%).
Return on Equity
High ROE: A260660 has a negative Return on Equity (-10.74%), as it is currently unprofitable.